TORRANCE

Virco Reports Full Year Revenue Increased 16.5% to $269.1 million, delivering 32.4% growth in Net Income

Retrieved on: 
Friday, April 12, 2024

Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.

Key Points: 
  • Net revenue for the full year ended January 31, 2024 increased 16.5% to $269.1 million from $231.1 million in the prior year.
  • For the seasonally light fourth quarter, revenue increased 9.8% to $42.6 million from $38.8 million.
  • Operating Income for the full year ended January 31, 2024 was $31.9 million compared to $10.6 million the prior year.
  • Total Net Income after taxes for the full year was $21.9 million compared to $16.5 million the prior year.

Canoo Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

Retrieved on: 
Monday, April 1, 2024

JUSTIN, Texas, April 01, 2024 (GLOBE NEWSWIRE) -- Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced its financial results for the fourth quarter and fiscal year 2023.

Key Points: 
  • JUSTIN, Texas, April 01, 2024 (GLOBE NEWSWIRE) -- Canoo Inc. (Nasdaq: GOEV), a high-tech advanced mobility company, today announced its financial results for the fourth quarter and fiscal year 2023.
  • “In Q4 2023, we started our first commercial fleet customer deliveries from our Oklahoma City manufacturing facility while we continue to prepare the site for our 20,000 unit run-rate production target.
  • Our strategy to purchase manufacturing assets at deep discounts creates immediate shareholder value.
  • A telephone replay will be available until April 15, 2024, at (877) 660-6853 (U.S.) and (201) 612-7415 (international callers/U.S.

Lundquist Investigator Dr. Yoshihara Awarded $3 Million NIH R01 Grant for Diabetes Stem Cell Therapy Research

Retrieved on: 
Monday, April 1, 2024

This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.

Key Points: 
  • This prestigious NIH R01 grant, known for its rigorous peer-review process, is dedicated to advancing stem cell therapy research for treating diabetes.
  • Insulin-dependent diabetes, including autoimmune Type 1 and stress-induced Type 2, presents a significant health burden, often necessitating lifelong insulin therapy and glucose monitoring.
  • Dr. Yoshihara's research focuses on the potential of human pluripotent stem cells (hPSCs) to create functional islet cells.
  • “Despite significant progress in stem cell-derived mini-organ technologies, we are still challenged by their functional immaturity and variability,” said Dr. Yoshihara.

Virco Issues Updated Investor Presentation

Retrieved on: 
Monday, April 1, 2024

Corporation (NASDAQ: VIRC) (the “Company”), the nation’s largest manufacturer and supplier of educational furniture and equipment, today issued an update of its investor presentation, highlighting the Company’s strong recovery following pandemic-related school closures.

Key Points: 
  • Corporation (NASDAQ: VIRC) (the “Company”), the nation’s largest manufacturer and supplier of educational furniture and equipment, today issued an update of its investor presentation, highlighting the Company’s strong recovery following pandemic-related school closures.
  • The investor update is available on the Company’s website at www.virco.com.
  • The investor presentation includes preliminary, unaudited financial results for the Company’s Fiscal Year Ended January 31, 2024.
  • During the course of that process, Virco may identify items that would require it to make adjustments, which may be material, to the information in this press release.

Navitas Delivers Grid-Connected Energy with 3.3 kV SiC and Bi-directional GaN ICs at PE International 2024

Retrieved on: 
Wednesday, March 27, 2024

Grid reliability is a key factor in a $1.3 trillion power semiconductor opportunity as Navitas’ technologies accelerate the transition from fossil fuels to renewable energies.

Key Points: 
  • Grid reliability is a key factor in a $1.3 trillion power semiconductor opportunity as Navitas’ technologies accelerate the transition from fossil fuels to renewable energies.
  • Navitas will introduce the latest GaNFast™ and GeneSiC™ products to the European audience, including new Gen-3 Fast SiC for high-power and higher-speed performance, plus GaNSafe™ - the world’s most protected GaN power devices.
  • Navitas will present the following on April 17th:
    "3.3 kV SiC MOSFETs Accelerate Grid-Connected Energy Storage," Dr. Ranbir Singh, EVP GeneSiC
    Synopsis: The grid supplies energy from generators and delivers it to customers via transmission and distribution (T&D) networks.
  • SiC inverters will revolutionize electricity delivery, renewable energy integration, and energy storage.

Yoshinoya and Botrista Double Down on Boba Tea With New Flavors, Sizes & Ingredients

Retrieved on: 
Tuesday, March 26, 2024

In partnership with Botrista , a pioneer in the world of beverage-making, Yoshinoya began testing Boba Tea in select restaurants in late 2022.

Key Points: 
  • In partnership with Botrista , a pioneer in the world of beverage-making, Yoshinoya began testing Boba Tea in select restaurants in late 2022.
  • And to celebrate, the brand will be giving away 1 million Boba Teas for FREE during the month of April.
  • As part of Yoshinoya’s Boba menu expansion, starting the first week in April, customers can indulge in a new flavor of Boba Tea, Mango Lemonade.
  • Yoshinoya and Botrista harnessed Michelin-star chef, Rex Huang, in the development of the new flavor of Boba Tea.

TLI Investigator Dr. Nicholas Jenzjowsky Receives NIH/NIAID Grant to Investigate the Neural Regulation of Asthma

Retrieved on: 
Wednesday, March 20, 2024

The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.

Key Points: 
  • The grant will fund the innovative project "Asthmatic inflammation requires neuronal upregulation of B-cells," which commenced this month and will run until January 2025.
  • This groundbreaking research aims to delve into the complexities of asthma and its symptoms, a major global health concern that requires a deeper understanding of its underlying mechanisms.
  • The innovative nature of this project underscores TLI's commitment to cutting-edge science and the potential impact of the research.
  • It aims to uncover potential drug targets and inform new strategies to mitigate the growing problem of allergic asthma.

TLI Investigator Dr. Wei Yan Named Editor-in-Chief of the Andrology Journal

Retrieved on: 
Monday, March 18, 2024

Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.

Key Points: 
  • Dr. Yan's appointment to Andrology is a testament to his dedication to reproductive medicine.
  • With over 160 peer-reviewed publications and numerous awards, Dr. Yan is a committed researcher and educator.
  • Dr. Yan's vision for Andrology is to enhance its global influence and implement innovative strategies.
  • His plans include prioritizing cutting-edge reviews, rewarding high-quality contributions, and fostering the next generation of researchers through the Trainee Reviewer Program.

Navitas “Electrify Our World™” at Asia’s Premier Charging Expo

Retrieved on: 
Wednesday, March 13, 2024

Visitors will explore the latest advances in GaN and SiC toward a fully-electrified "Planet Navitas" and the transition from fossil fuels.

Key Points: 
  • Visitors will explore the latest advances in GaN and SiC toward a fully-electrified "Planet Navitas" and the transition from fossil fuels.
  • Many more GaNFast™ chargers will be displayed for visitors to experience the lightning speed of GaNFast charging.
  • Visitors to "Planet Navitas" (booth B57-B60) will meet experienced Navitas engineers to explore the power of next-gen power semiconductors for leading-edge applications.
  • “Our latest, advanced GaNFast and GeneSiC technologies bring revolutionary fast-charging capabilities to industry-leading Chinese customers.”
    To schedule meetings with Navitas at ACE 2024, please contact: [email protected] , or alternatively, book a meeting through Navitas’ booking calendar: https://calendly.com/navitas-asia-charging-expo-2024/meeting

Navitas GaN and SiC Technologies to Enable Next-Gen AI Power Delivery

Retrieved on: 
Monday, March 11, 2024

To meet this exponential power increase, Navitas is developing server power platforms which rapidly increase from 3kW to up to 10kW.

Key Points: 
  • To meet this exponential power increase, Navitas is developing server power platforms which rapidly increase from 3kW to up to 10kW.
  • In August 2023, Navitas introduced a 3.2kW data center power platform utilizing latest GaN technology enabling over 100W/in3 and over 96.5% efficiency.
  • Today, Navitas also announces its plans to introduce an 8-10kW power platform by the end of 2024 to support 2025 AI power requirements.
  • The platform will utilize newer GaN and SiC technologies and further advances in architecture to set all-new industry standards in power density, efficiency and time-to-market.